Louis Matis takes up the position at the biotechnology company
Pieris Pharmaceuticals, a biotechnology company developing biotherapeutics through its proprietary Anticalin technology platform, has appointed Louis Matis as Senior Vice President and Chief Development Officer.
Prior to joining Pieris, from June 2011, Matis was Executive Director, Strategic Evaluation at Alexion Pharmaceuticals.
He also worked at Alexion from 1993 to 2000, during which time he advanced to the position of Chief Scientific Officer.
Before re-joining Alexion in 2011, Matis was CEO of CGI Pharmaceuticals, from 2000 to 2006, and of the Immune Tolerance Institute from 2007 to 2010.
From 1977 until joining Alexion in 1993, Matis held senior research and clinical positions at the National Cancer Institute (NCI), National Institutes of Health (NIH), in Bethesda, MD, and the FDA Center for Biologics Evaluation and Research (CBER).